The Value of Drug Repositioning: Longer Patent Life

According to Gene Logic, there's value in failed Phase II candidates-so long as safety's not the problem. The company claims that repositioning a compound in a new indication creates an asset worth 27% more, in net present value terms, than an equivalent in-licensed drug.

At last, some good news for those companies struggling with late-stage trial setbacks. According to Gene Logic Inc. , there’s value in failed Phase II candidates—so long as safety is not the problem. The company claims that repositioning a compound in a new indication creates an asset worth 27% more, in net present value terms, than an equivalent in-licensed drug.

With rising development costs, spluttering pipelines and soaring deal prices, the concept of recycling assets is gaining traction amid pharmaceutical...

More from Business Strategy

More from In Vivo